HLA-B17 and the HLA-A1, B17 Haplotype in Acute Myelogenous Leukemia

Publisher Website
Google Scholar
Abstract
Caucasians [79] with acute myelogenous leukemia (AML) were genotyped to determine whether AML and the induction of remission or patient survival were associated with particular HLA phenotypes or haplotypes. HLA-B17 and B27 were increased in AML patients over 40 yr of age. Combined analysis of 4 independent studies indicates that HLA-B17 is significantly but weakly associated with AML; relative risk = 1.48 (.01 < P < .025). The A1, B17 and Aw24, Bw35 haplotypes occurred more frequently in the AML group as compared to racial and geographic controls (uncorrected P = 0.0068 and 0.0098, respectively, Fisher''s Exact Test). Induction of remission occurred less frequently in patients with the B17 phenotype as compared to patients lacking this antigen (P = 0.047). Patient survival was associated with remission status (P = 0.002) but was not significantly associated with particular HLA phenotypes or haplotypes. A gene or genes in the HLA-B region of the major histocompatibility complex can apparently influence susceptibility to AML and also the response to chemotherapy.

This publication has 4 references indexed in Scilit: